Clinuvel Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Clinuvel Pharmaceuticals CEO ist Philippe Wolgen , ernannt in Nov 2005, hat eine Amtszeit von 19.08 Jahren. Die jährliche Gesamtvergütung beträgt A$3.74M , bestehend aus 47.2% Gehalt und 52.8% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 6.86% der Aktien des Unternehmens, im Wert von A$46.65M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 0.9 Jahre bzw. 5 Jahre.

Wichtige Informationen

Philippe Wolgen

Geschäftsführender

AU$3.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	47.2%
Amtszeit als Geschäftsführer	19yrs
Eigentum des Geschäftsführers	6.9%
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	5yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Philippe Wolgen im Vergleich zu den Einnahmen von Clinuvel Pharmaceuticals verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	AU$4m	AU$2m	AU$36m
Mar 31 2024	n/a	n/a	AU$33m
Dec 31 2023	n/a	n/a	AU$30m
Sep 30 2023	n/a	n/a	AU$30m
Jun 30 2023	AU$6m	AU$2m	AU$31m
Mar 31 2023	n/a	n/a	AU$29m
Dec 31 2022	n/a	n/a	AU$26m
Sep 30 2022	n/a	n/a	AU$24m
Jun 30 2022	AU$7m	AU$1m	AU$21m
Mar 31 2022	n/a	n/a	AU$22m
Dec 31 2021	n/a	n/a	AU$24m
Sep 30 2021	n/a	n/a	AU$24m
Jun 30 2021	AU$5m	AU$2m	AU$25m
Mar 31 2021	n/a	n/a	AU$23m
Dec 31 2020	n/a	n/a	AU$21m
Sep 30 2020	n/a	n/a	AU$18m
Jun 30 2020	AU$3m	AU$2m	AU$15m
Mar 31 2020	n/a	n/a	AU$15m
Dec 31 2019	n/a	n/a	AU$15m
Sep 30 2019	n/a	n/a	AU$16m
Jun 30 2019	AU$1m	AU$894k	AU$18m
Mar 31 2019	n/a	n/a	AU$17m
Dec 31 2018	n/a	n/a	AU$16m
Sep 30 2018	n/a	n/a	AU$15m
Jun 30 2018	AU$2m	AU$818k	AU$13m

Vergütung im Vergleich zum Markt: PhilippeDie Gesamtvergütung ($USD2.43M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Australian ($USD928.86K).

Entschädigung vs. Einkommen: PhilippeDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Philippe Wolgen (61 yo)

19yrs

Amtszeit

AU$3,742,412

Vergütung

Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Philippe Wolgen	CEO, MD & Director	19yrs	AU$3.74m	6.86% A$ 46.7m
Dennis Wright	Chief Scientific Officer	12.2yrs	AU$782.61k	0.38% A$ 2.6m
Peter Vaughan	Chief Financial Officer	less than a year	keine Daten	keine Daten
Lachlan Hay	Chief Operations Officer	no data	keine Daten	keine Daten
Malcolm Bull	Head of Australian Operations & Investor Relations	no data	keine Daten	keine Daten
Rose Quadbeck-Diel	Senior Vice President of Regulatory Affairs	less than a year	keine Daten	keine Daten
Azza Hamila	Head of Quality Assurance & Drug Safety	less than a year	keine Daten	keine Daten
Claire Newstead-Sinclair	Company Secretary	less than a year	keine Daten	keine Daten

0.9yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: CUVDas Führungsteam des Unternehmens gilt nicht als erfahren ( 0.9 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Philippe Wolgen	CEO, MD & Director	19.1yrs	AU$3.74m	6.86% A$ 46.7m
Pearl Grimes	Non-Executive Director	less than a year	keine Daten	keine Daten
Matthew Pringle	Non-Executive Director	less than a year	keine Daten	keine Daten
Susan Smith	Non-Executive Director	5.2yrs	AU$80.00k	0.00084% A$ 5.7k
Jeffrey Rosenfeld	Non-Executive Chairman	5yrs	AU$91.67k	0.0063% A$ 42.9k
Karen Agersborg	Non-Executive Director	6.8yrs	AU$75.00k	0.028% A$ 188.4k
Guy van Dievoet	Non-Executive Director	less than a year	keine Daten	keine Daten

5.0yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrener Vorstand: CUVDie Vorstandsmitglieder gelten als erfahren (5 Jahre durchschnittliche Amtszeit).

Clinuvel Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

No independent directors

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Recent updates

CLINUVEL Files Canadian New Drug Submission for SCENESSE® in EPP

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 16, 2024

Dividend of AU$0.05 announced

Full year 2024 earnings released: EPS: AU$0.71 (vs AU$0.62 in FY 2023)

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Clinuvel Pharmaceuticals Limited Announces Change of Company Secretary

CLINUVEL Announces A Novel Clinical Program

Investor sentiment deteriorates as stock falls 17%

First half 2024 earnings released: EPS: AU$0.22 (vs AU$0.23 in 1H 2023)

Clinuvel Pharmaceuticals Limited to Report First Half, 2024 Results on Feb 22, 2024

Clinuvel Pharmaceuticals Limited Announces Board Changes

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 31, 2023

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023

Full year 2023 earnings released: EPS: AU$0.62 (vs AU$0.42 in FY 2022)

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Aug 29, 2023

Investor sentiment deteriorates as stock falls 19%

Now 22% undervalued

Clinuvel Pharmaceuticals Ltd Announces the Completion of Manufacture of the First cGMP Batch of PRÉNUMBRA® Instant

Clinuvel Pharmaceuticals Limited Announces First Positive Results from Study Evaluating the Protective Effects of Afamelanotide on Skin Exposed to Ultraviolet Radiation

Clinuvel Pharmaceuticals Limited Announces Neuracthel Manufacturing Processes Advance

Clinuvel Pharmaceuticals Limited Shares the First Results of Phase II Study Evaluating Afamelanotide in Patients with Xeroderma Pigmentosum

No independent directors

Clinuvel Pharmaceuticals Limited Announces Enrollment of First Patient in New Clinical Study CUV104

Investor sentiment improved over the past week

Clinuvel Pharmaceuticals Limited, Annual General Meeting, Oct 26, 2022

Full year 2022 earnings released: EPS: AU$0.42 (vs AU$0.50 in FY 2021)

Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2022, Payable on September 21, 2022

Investor sentiment improved over the past week

CLINUVEL PHARMACEUTICALS LIMITED Intends to Evaluate its Drug Candidate PRÉNUMBRA Instant (Afamelanotide) as A Treatment for Patients Diagnosed with Arterial Ischaemic Stroke (AIS) in its Next Clinical Trial (CUV803)

Investor sentiment improved over the past week

Non-Executive Director recently sold AU$356k worth of stock

CLINUVEL Progresses CUV104 Vitiligo Study

CLINUVEL Releases Positive Final Results of the Open Label Pilot Study (CUV801) in Arterial Ischemic Stroke

No independent directors

Clinuvel Pharmaceuticals Ltd Appoints Andrew Likierman as New Non-Executive Director

Clinuvel Pharmaceuticals Limited Announces First XP-V Patient Treated in Third CUV DNA Repair Study

CEO, MD & Director recently sold AU$1.1m worth of stock

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Now 28% undervalued after recent price drop

Clinuvel Pharmaceuticals Limited Completes Enrolment in CUV801 Stroke Study

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS AU$0.50 (vs AU$0.31 in FY 2020)

CEO, MD & Director recently sold AU$3.7m worth of stock

Non-Executive Director recently sold AU$692k worth of stock

Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with Afamelanotide

CEO, MD & Director recently sold AU$3.1m worth of stock

CEO, MD & Director recently sold AU$2.6m worth of stock

Clinuvel Pharmaceuticals Limited to Report Fiscal Year 2021 Results on Aug 31, 2021

Investor sentiment improved over the past week

Revenue misses expectations

First half 2021 earnings released: EPS AU$0.13 (vs AU$0.013 in 1H 2020)

New 90-day low: AU$20.11

Clinuvel Pharmaceuticals Limited to Report First Half, 2021 Results on Feb 26, 2021

Clinuvel Pharmaceuticals Limited Announces First Patient Dosed in SCENESSE DNA Repair Program

New 90-day low - AU$21.04

Earnings released

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit